Navigation Links
Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
Date:6/25/2008

'First-to-File' Status Will Provide 180-Day Marketing Exclusivity Upon

Final Approval

PRINCETON, N.J., June 25 /PRNewswire/ -- Ranbaxy Laboratories Limited (RLL), announced today that the company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valganciclovir Hydrochloride Tablets, 450 mg. Total annual market sales for Valganciclovir HCl Tablets were $239 million (IMS - MAT: March 2008).

Ranbaxy believes that it has First-to-File status on Valganciclovir tablets, thereby providing a potential of 180-days of marketing exclusivity, offering a significant opportunity in the future.

Valganciclovir HCl Tablets are indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). Valganciclovir HCl is also indicated for the prevention of cytomegalovirus (CMV) disease in kidney, heart and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [(D+/R-)]).

"Ranbaxy is pleased to receive this tentative approval for Valganciclovir Hydrochloride Tablets, a medicine that has established its clinical value and utility over time. It will be launched by Ranbaxy upon receiving final approval and resolution of litigation currently pending in Federal District Court, as an affordably priced alternative to the branded product, Valcyte. This product formulation will further expand our portfolio of affordable generic alternatives and will be available to all classes of trade," said Bill Winter, Vice President of Trade Sales for RPI, USA. "This represents another potentially strong market entry for Ranbaxy medicines from among our pipeline of patent challenges, and offers us a significant future opportunity," Winter added.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India
'/>"/>

SOURCE Ranbaxy Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
2. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
4. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
5. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
6. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
7. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
8. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
9. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. N-Viro International Corporation Announces Dismissal of Lawsuit Against It
11. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Inc., a developer of innovative therapeutics for diseases ... results for the company,s lead product candidate, OTO-104, ... demonstrated that a single intratympanic (IT) injection of ... corticosteroid dexamethasone, provided significant protection against both noise-induced ...
... Feb. 22, 2011 Jennerex, Inc. (San ... appointment of James M. Burke, M.D. to the newly-created ... be responsible for all global clinical research activities related ... has been working with Jennerex in an advisory capacity ...
... KONG, Feb. 22, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ... first and largest cord blood banking operator in China, today ... was held on February 18, 2011, in Hong Kong. ... Albert Chen and Mark Chen to serve on the Board ...
Cached Biology Technology:Otonomy's OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies 2Otonomy's OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies 3Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research 2China Cord Blood Corporation Announces Results of 2010 Annual General Meeting 2
(Date:7/9/2014)... on the verge of an economy driven by methane, the ... and is undergoing a production boom. It has poised the ... is casting serious doubts over just how climate-friendly it is, ... (C&EN), the weekly news magazine of the American Chemical ... at C&EN, explains that when burned as a fuel to ...
(Date:7/9/2014)... Can thyroid hormone protect neuronal function and increase ... Ailing Fu and her team, School of Pharmaceutical ... in which aged mice were administered with low ... showed that the aged rats exhibited an obvious ... rate from 60% to 93%. The underlying mechanism ...
(Date:7/9/2014)... They are amongst the most numerous inhabitants of the ... . Not visible to the naked eye, when they ... sized patches, they are even visible on satellite images. ... responsible for approximately half of the global photosynthesis output," ... University Jena (Germany). In the process the greenhouse gas ...
Breaking Biology News(10 mins):Short circuit in the food web 2
... of scientists, including University of Colorado School of Medicine ... disease related to an inability to process Vitamin B12. ... "Some people with rare inherited conditions cannot process vitamin ... a geneticist and senior author of a paper about ...
... key role in preserving biological diversity. A new study carried ... (SLU), among others, indicates that if the world,s religious leaders ... positioned to do so. Our study investigates how ... they overlap areas that are important for global biological diversity, ...
... $4.5 million over the next five years for a ... detecting disorders and conditions can and should become a ... one of four projects launched today by the National ... providing genetic sequencing as part of, or instead of, ...
Cached Biology News:Peering into genetic defects, CU scientists discover a new metabolic disease 2Peering into genetic defects, CU scientists discover a new metabolic disease 3Religious leaders can be key to biological diversity 2UCSF receives $4.5M to study value of gene sequencing in newborns 2UCSF receives $4.5M to study value of gene sequencing in newborns 3UCSF receives $4.5M to study value of gene sequencing in newborns 4
... The APO-BRDU Kit is a two ... and total cellular DNA to detect apoptotic ... the instructions and reagents required for measuring ... control cells for assessing reagent performance; washing, ...
... CHEMICON APO-BRDU Kit is a ... breaks and total cellular DNA to detect ... kit contains the instructions and reagents required ... and negative control cells for assessing reagent ...
... with temperature probe, 100-120 and 220-240 V, supports ... and 400 W. The temperature probe is used ... degrees C during electrophoresis. Built-in infrared capability allows ... are provided. Dimensions are 27.5 x 34 x ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Biology Products: